SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

Correspondence 0001104659-25-011313 from Petros Pharmaceuticals, Inc. (PTPI)

Petros Pharmaceuticals, Inc.
Date: Feb. 11, 2025 · CIK: 0001815903 · Accession: 0001104659-25-011313

AI Filing Summary & Sentiment

File numbers found in text: 333-284495

Date
February 11, 2025
Author
Not clearly detected
Form
CORRESP
Company
Petros Pharmaceuticals, Inc.

Letter

Dawson James Securities, Inc.

101 North Federal Highway, Suite 600

Boca Raton, Fl 33432

February 11, 2025

VIA EDGAR CORRESPONDENCE

U.S. Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

Re: Petros Pharmaceuticals, Inc.

Registration Statement on Form S-1/A

File No. 333-284495

Ladies and Gentlemen:

Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended (the “Act”), we, the placement agent, hereby request that the Securities and Exchange Commission (the “Commission”) take appropriate action to cause the above-referenced registration statement on Form S-1/A (the “Registration Statement”) to become effective at 4:00 p.m., Eastern Time, on Wednesday, February 12, 2025 or as soon thereafter as practicable.

Pursuant to Rule 460 under the Act, we wish to advise you that we have distributed as many copies of the Preliminary Prospectus dated February 10, 2025 to agents, dealers, institutions and others as appears to be reasonable to secure adequate distribution of the preliminary prospectus.

The undersigned, as placement agent, has complied and will comply with Rule 15c2-8 under the Securities Exchange Act of 1934, as amended.

If you require any additional information with respect to this letter, please contact Ali Panjwani at (212) 326-0820 of Pryor Cashman LLP.

Very truly yours,
DAWSON JAMES SECURITIES, INC.

Show Raw Text
CORRESP
1
filename1.htm

Dawson
James Securities, Inc.

101 North
Federal Highway, Suite 600

Boca
Raton, Fl 33432

February 11, 2025

VIA EDGAR CORRESPONDENCE

U.S. Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

 Re: Petros Pharmaceuticals, Inc.

Registration Statement on Form S-1/A

File No. 333-284495

Ladies and Gentlemen:

Pursuant to Rule 461 of the
General Rules and Regulations under the Securities Act of 1933, as amended (the “Act”), we, the placement agent, hereby request
that the Securities and Exchange Commission (the “Commission”) take appropriate action to cause the above-referenced registration
statement on Form S-1/A (the “Registration Statement”) to become effective at 4:00 p.m., Eastern Time, on Wednesday, February
12, 2025 or as soon thereafter as practicable.

Pursuant to Rule 460 under
the Act, we wish to advise you that we have distributed as many copies of the Preliminary Prospectus dated February 10, 2025 to agents,
dealers, institutions and others as appears to be reasonable to secure adequate distribution of the preliminary prospectus.

The undersigned, as placement
agent, has complied and will comply with Rule 15c2-8 under the Securities Exchange Act of 1934, as amended.

If you require any additional
information with respect to this letter, please contact Ali Panjwani at (212) 326-0820 of Pryor Cashman LLP.

    Very truly yours,

    DAWSON JAMES SECURITIES, INC.

    By:
    /s/ Robert D. Keyser, Jr.

    Robert D. Keyser, Jr.

    Chief Executive Officer

 cc: M. Ali Panjwani, Esq.

Pryor Cashman LLP